^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | ProstAtak (aglatimagene besadenovec) (Gene transference, Thymidine kinase stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
Published date:
12/12/2023
Excerpt:
Candel Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.
